Correction to: Oncogene
The original version of this Article omitted the following from the Acknowledgements:
Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare.
This has now been corrected in both the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Jin, Y., Bao, H., Le, X. et al. Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39, 2027 (2020). https://doi.org/10.1038/s41388-019-1143-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41388-019-1143-5